Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate Eras-007 and Encorafenib Combination

0
154
Erasca, Inc. announced a clinical trial collaboration and supply agreement with Pierre Fabre for the BRAF inhibitor encorafenib, BRAFTOVI®, within key international territories.
[Erasca, Inc.]
Press Release